Experimental antibody aims to repair brain connections in rare dementia
NCT ID NCT07154485
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study tests a new drug called NS101 in 15 people with semantic variant primary progressive aphasia (svPPA), a rare type of frontotemporal dementia that affects language and memory. The drug is an antibody designed to help repair connections between brain cells. The main goal is to check safety, but researchers will also look for signs that it might slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NS101 (an antibody that may help repair brain cell connections)
- What this could lead to
- If it works, this could point toward a treatment that slows or improves language and thinking problems in people with this rare form of dementia.
- What could go wrong
- This is a very early, small study (15 people) focused mainly on safety. It may not show any benefit, and the drug could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2025
An estimate. Start dates often move.
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
55 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Participants diagnosed at screening with mild to moderate frontotemporal dementia, semantic variant (svFTD), defined by a CDR® Plus NACC FTLD Sum of Boxes (SOB) score between 4.5 and 15.5. * Participants confirmed to be amyloid-negative based on Amyloid PET scan or CSF results within the past 36 months. Key Exclusion Criteria: * Participants with other degenerative brain diseases as determined by the investigator * Participants with other neurological disorders and uncontrolled acute disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Dementia, frontotemporal are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.